Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis
PIRA and RAW in their current definitions do not reliably distinguish between disability worsening due to inflammatory disease activity and neurodegeneration in RRMS. In addition, PIRA and RAW have similar and troubling issues of random variation and measurement error as currently used trial outcome measures. Our analysis requires confirmation in other clinical data sets; a meaningful next step would be to study the co-occurrence of PIRA with radiologic disease activity in a setting with more comprehensive MRI monitoring.
Authors
- Jop Mostert (ORCID: https://orcid.org/0000-0003-3640-9935)
- Marcus Koch (ORCID: https://orcid.org/0000-0001-9972-5092)
- Pavle Repovic (ORCID: https://orcid.org/0000-0001-7358-6872)
- Bernard M.J. Uitdehaag (ORCID: https://orcid.org/0000-0002-9226-7364)
- Eva M. M. Strijbis (ORCID: https://orcid.org/0000-0001-6705-5864)
- Amber R. Salter (ORCID: https://orcid.org/0000-0002-1088-110X)
- Gary Cutter (ORCID: https://orcid.org/0000-0002-8455-980X)
- James D. Bowen (ORCID: https://orcid.org/0000-0002-4258-250X)
- Jacynthe Comtois (ORCID: https://orcid.org/0000-0002-7748-6104)
Institutions
- University of Calgary (CA)
- University of Alabama at Birmingham (US)
- Swedish Medical Center (US)
- Amsterdam University Medical Centers (NL)
- Rijnstate Hospital (NL)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Neurology
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1212/wnl.0000000000210153
- Citations
- 5
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.12
Funders
- U.S. Department of Defense
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- University of Pennsylvania
- CSL Behring
- Regeneron Pharmaceuticals
- TG Therapeutics
- GW Pharmaceuticals
- Horizon Pharmaceuticals
- AveXis
- Prothena
- Multiple Sclerosis Society of Canada
- Multiple Sclerosis Society
- Mitsubishi Tanabe Pharma Corporation
- Genentech
- EMD Serono
- Sanofi Genzyme